The pharmacogenetics of treatment with olanzapine-Reference-Cited by-同舟云学术

The pharmacogenetics of treatment with olanzapine

Published:2021-09 Issue:14 Volume:22 Page:939-958
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Zubiaur Pablo¹²^ORCID,Soria-Chacartegui Paula¹^ORCID,Villapalos-García Gonzalo¹^ORCID,Gordillo-Perdomo Juan J³,Abad-Santos Francisco¹²⁴^ORCID

Affiliation:

1. Department of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain

2. UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain

3. Department of Clinical Analysis, Hospital Universitario de La Princesa, Madrid, 28006, Spain

4. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28006, Spain

Abstract

Genetic polymorphism in olanzapine-metabolizing enzymes, transporters and drug targets is associated with alterations in safety and efficacy. The aim of this systematic review is to describe all clinically relevant pharmacogenetic information on olanzapine and to propose clinically actionable variants. Two hundred and eighty-four studies were screened; 76 complied with the inclusion criteria and presented significant associations. DRD2 Taq1A (rs1800497) *A1, LEP -2548 (rs7799039) G and CYP1A2*1F alleles were related to olanzapine effectiveness and safety variability in several studies, with a high level of evidence. DRD2 –141 (rs1799732) Ins, A-241G (rs1799978) G, DRD3 Ser9Gly (rs6280) Gly, HTR2A rs7997012 A, ABCB1 C3435T (rs1045642) T and G2677T/A (rs2032582) T and UGT1A4*3 alleles were related to safety, effectiveness and/or pharmacokinetic variability with moderated level of evidence.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2021-0051

Reference108 articles.

1. Olanzapine

2. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia

3. European Medicines Agency. Zyprexa, olanzapine drug label. https://www.ema.europa.eu/en/medicines/human/EPAR/zyprexa

4. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics;The World Journal of Biological Psychiatry;2024-09

2. Formulation, in vitro and in vivo evaluation of olanzapine nanoparticles dissolving microneedles for transdermal delivery;Pharmacia;2024-05-29

3. Preparation and Optimization of Olanzapine as Transdermal Nanoparticles Delivery System;Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 );2024-05-15

4. Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics;Frontiers in Psychiatry;2024-03-19

5. Human Data on Pharmacokinetic Interactions of Cannabinoids: A Narrative Review;Current Pharmaceutical Design;2024-02